Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | GSK3A | P49840 | 1/20 | 0.72 |
| ▸ | GSK3B | P49841 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | PDE5A | O76074 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945461 | 0.93 | MEN1 (0.97) | ABCG2MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL22201624 | 0.91 | ABCG2 (0.83) | ABCG2MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL5526966 | 0.87 | MEN1 (0.82) | ABCG2MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL13945465 | 0.87 | MEN1 (0.82) | ABCG2MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL7434986 | 0.85 | ALDH1A1 (1.00) | ABCG2MEN1KMT2AABCB1ALDH1A1 | |
| SCHEMBL1083761 | 0.84 | HPGD (1.00) | ABCG2ABCB1ALDH1A1POLBHPGD | |
| SCHEMBL1083768 | 0.83 | KDM4E (1.00) | ABCG2ABCB1ALDH1A1POLBHPGD | |
| SCHEMBL22201579 | 0.83 | ABCG2 (0.85) | ABCG2MEN1KMT2AABCB1ALDH1A1 | |
| SCHEMBL1083771 | 0.83 | MEN1 (0.98) | ABCG2MEN1KMT2AABCB1L3MBTL1 | |
| SCHEMBL15977127 | 0.83 | ABCG2 (0.84) | ABCG2MEN1KMT2AABCB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | claimed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | claimed |
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| WO-1999059584-A1 | COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | SCHERING CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | ABCG2 3440/4885MEN1 893/4885KMT2A 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.